{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:56:29Z","timestamp":1768856189611,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Postgraduate Scientific Research Innovation Project of Hunan Province","award":["CX20210974"],"award-info":[{"award-number":["CX20210974"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ5513"],"award-info":[{"award-number":["2020JJ5513"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific research Fund of hunan provincial education department","award":["19A418"],"award-info":[{"award-number":["19A418"]}]},{"name":"Scientific Research\u00a0Fund\u00a0Project\u00a0of\u00a0Hunan\u00a0Provinci al Health\u00a0Commission","award":["20201973"],"award-info":[{"award-number":["20201973"]}]},{"name":"Central government funds for guiding local scientific and Technological Development","award":["2021QZY016"],"award-info":[{"award-number":["2021QZY016"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823"],"award-info":[{"award-number":["2020SK51823"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10637-022-01300-z","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T07:12:14Z","timestamp":1662621134000},"page":"1333-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CD25-targeted antibody\u2013drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"40","author":[{"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangzhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunbo","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"issue":"2","key":"1300_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68(2):116\u2013132","journal-title":"CA Cancer J Clin"},{"key":"1300_CR2","unstructured":"American Cancer Society (2022) Types of Hodgkin lymphoma. https:\/\/www.cancer.org\/cancer\/hodgkin-lymphoma\/about\/what-is-hodgkin-disease.html. Accessed June 2022"},{"issue":"1","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"key":"1300_CR4","unstructured":"American Cancer Society (2022) Key Statistics for Hodgkin Lymphoma. https:\/\/www.cancer.org\/cancer\/hodgkin-lymphoma\/about\/key-statistics.html. Accessed June 2022"},{"issue":"15","key":"1300_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","volume":"131","author":"A Mottok","year":"2018","unstructured":"Mottok A, Steidl C (2018) Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 131(15):1654\u20131665","journal-title":"Blood"},{"issue":"15","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2017-09-772681","volume":"131","author":"N Mehta-Shah","year":"2018","unstructured":"Mehta-Shah N, Bartlett NL (2018) Management of relapsed\/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood 131(15):1698\u20131703","journal-title":"Blood"},{"issue":"11","key":"1300_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","volume":"34","author":"F Merli","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG et al (2016) Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol 34(11):1175\u20131181","journal-title":"J Clin Oncol"},{"issue":"3","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/joim.12582","volume":"281","author":"I Glimelius","year":"2017","unstructured":"Glimelius I, Diepstra A (2017) Novel treatment concepts in Hodgkin lymphoma. J Intern Med 281(3):247\u2013260","journal-title":"J Intern Med"},{"issue":"10","key":"1300_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11864-016-0428-y","volume":"17","author":"D Jagadeesh","year":"2016","unstructured":"Jagadeesh D, Smith MR (2016) Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma. Curr Treat Options Oncol 17(10):55","journal-title":"Curr Treat Options Oncol"},{"key":"1300_CR10","unstructured":"Adcetris Press release (2022) Seattle Genetics, Inc. https:\/\/www.seagen.com\/search?q=Adcetris. Accessed June 2022"},{"issue":"12","key":"1300_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE et al (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566","journal-title":"Blood"},{"issue":"4","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A et al (2021) Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 22(4):512\u2013524","journal-title":"Lancet Oncol"},{"issue":"4","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"6","key":"1300_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL et al (2021) Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 138(6):427\u2013438","journal-title":"Blood"},{"issue":"1","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11899-021-00604-w","volume":"16","author":"N Epperla","year":"2021","unstructured":"Epperla N, Hamadani M (2021) A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. Curr Hematol Malig Rep 16(1):19\u201324","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"1300_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.transci.2011.01.016","volume":"44","author":"K Paulson","year":"2011","unstructured":"Paulson K, Szwajcer D, Seftel MD (2011) The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Transfus Apher Sci 44(2):197\u2013203","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","volume":"35","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L et al (2021) Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 35(9):2672\u20132683","journal-title":"Leukemia"},{"issue":"7","key":"1300_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","volume":"21","author":"JA Hartley","year":"2021","unstructured":"Hartley JA (2021) Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther 21(7):931\u2013943","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A (2021) Loncastuximab Tesirine: First Approval. Drugs 81(10):1229\u20131233","journal-title":"Drugs"},{"issue":"11","key":"1300_CR20","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn MJ, Zammarchi F, Tyrer PC et al (2016) ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther 15(11):2709\u20132721","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1300_CR21","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","volume":"8","author":"JA Hartley","year":"2018","unstructured":"Hartley JA, Flynn MJ, Bingham JP et al (2018) Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep 8(1):10479","journal-title":"Sci Rep"},{"key":"1300_CR22","unstructured":"ADC Therapeutics SA (2022) A robust pipeline of ADCs for the treatment of hematological cancers and solid tumors. https:\/\/www.adctherapeutics.com\/our-pipeline\/#cami. Accessed June 2022"},{"issue":"6","key":"1300_CR23","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","volume":"8","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Collins GP, Caimi PF et al (2021) Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol 8(6):e433\u2013e445","journal-title":"Lancet Haematol"},{"key":"1300_CR24","doi-asserted-by":"crossref","unstructured":"Zinzani P L, Carlo\u2010Stella C, Hamadani M et al (2021) Camidanlumab tesirine efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R\/R\u00a0cHL). Poster presented at: 16th International Conference on Malignant Lymphoma (ICML) Virtual Congress, June 18\u201322, 2021","DOI":"10.1002\/hon.75_2879"},{"key":"1300_CR25","unstructured":"Carlo\u2010Stella C, Ansell S, Zinzani PL et al (2022) Camidanlumab tesirine: updated\u00a0efficacy and safety\u00a0in an open-label,\u00a0multicenter,\u00a0phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R\/R\u00a0cHL). Poster presented at: European\u00a0Hematology\u00a0Association\u00a0Hybrid\u00a0Congress,\u00a0June\u00a09\u201012,\u00a02022"},{"key":"1300_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106385","volume":"95","author":"AD Goldberg","year":"2020","unstructured":"Goldberg AD, Atallah E, Rizzieri D et al (2020) Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res 95:106385","journal-title":"Leuk Res"},{"key":"1300_CR27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","volume":"132","author":"M Hamadani","year":"2018","unstructured":"Hamadani M, Collins GP, Samaniego F et al (2018) Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma [abstract plus poster]. Blood 132:928","journal-title":"Blood"},{"issue":"2","key":"1300_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000860","volume":"8","author":"F Zammarchi","year":"2020","unstructured":"Zammarchi F, Havenith K, Bertelli F, Vijayakrishnan B, Chivers S, van Berkel PH (2020) CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer 8(2):e000860","journal-title":"J Immunother Cancer"},{"key":"1300_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hon.134_2630","volume":"37","author":"F Spriano","year":"2019","unstructured":"Spriano F, Tarantelli C, Golino G et al (2019) The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines [abstract plus poster]. Hematol Oncol 37:323\u2013324","journal-title":"Hematol Oncol"},{"key":"1300_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2020-137004","volume":"136","author":"A Jabeen","year":"2020","unstructured":"Jabeen A, Huang S, Hartley JA et al (2020) Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models. Blood 136:31\u201332","journal-title":"Blood"},{"key":"1300_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-137011","volume":"136","author":"J Boni","year":"2020","unstructured":"Boni J, Havenith K, Hamadani M et al (2020) Pharmacokinetic and pharmacodynamic correlates from the phase 1 study of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma [abstract plus poster]. Blood 136:35\u201336","journal-title":"Blood"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.61_2629","volume":"37","author":"G Collins","year":"2019","unstructured":"Collins G, Horwitz S, Hamadani M et al (2019) Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (adct-301, cami) in relapsed\/refractory (r\/r) classical hodgkin lymphoma (CHL). Hematol Oncol 37:95\u201397","journal-title":"Hematol Oncol"},{"key":"1300_CR33","unstructured":"Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04052997. Accessed June 2022"},{"issue":"3","key":"1300_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ekir.2021.11.025","volume":"7","author":"NL Li","year":"2021","unstructured":"Li NL, Flores K, Prosek J, Brodsky SV, Ayoub I (2021) Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate. Camidanlumab Tesirine Kidney Int Rep 7(3):642\u2013646","journal-title":"Camidanlumab Tesirine Kidney Int Rep"},{"key":"1300_CR35","unstructured":"Study of ADCT-301 in Patients With Selected Advanced Solid Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03621982. Accessed June 2022"},{"key":"1300_CR36","unstructured":"ADCT-301 in Patients With R\/R AML, MDS, or MDS\/MPN. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639024. Accessed June 2022"},{"key":"1300_CR37","doi-asserted-by":"crossref","unstructured":"Calabretta E, Hamadani M, Carlo-Stella C (2022) The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large b-cell lymphoma.\u00a0Blood 2021014663","DOI":"10.1182\/blood.2021014663"},{"issue":"6","key":"1300_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790\u2013800","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01300-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01300-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01300-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:53:04Z","timestamp":1678510384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01300-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01300-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}